Mill Creek Capital Advisors LLC Acquires 1,144 Shares of Johnson & Johnson (NYSE:JNJ)

Mill Creek Capital Advisors LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 248,661 shares of the company’s stock after purchasing an additional 1,144 shares during the period. Johnson & Johnson accounts for about 0.9% of Mill Creek Capital Advisors LLC’s portfolio, making the stock its 18th biggest position. Mill Creek Capital Advisors LLC’s holdings in Johnson & Johnson were worth $35,961,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. First Fiduciary Investment Counsel Inc. boosted its holdings in Johnson & Johnson by 2.9% in the fourth quarter. First Fiduciary Investment Counsel Inc. now owns 95,515 shares of the company’s stock worth $13,813,000 after acquiring an additional 2,701 shares in the last quarter. Pineridge Advisors LLC boosted its holdings in Johnson & Johnson by 48.0% in the fourth quarter. Pineridge Advisors LLC now owns 780 shares of the company’s stock worth $113,000 after acquiring an additional 253 shares in the last quarter. Panoramic Capital Partners LLC bought a new position in Johnson & Johnson in the fourth quarter worth approximately $715,000. Arlington Trust Co LLC boosted its holdings in Johnson & Johnson by 15.3% in the fourth quarter. Arlington Trust Co LLC now owns 3,034 shares of the company’s stock worth $439,000 after acquiring an additional 403 shares in the last quarter. Finally, Global Wealth Management Investment Advisory Inc. boosted its holdings in Johnson & Johnson by 6.8% in the fourth quarter. Global Wealth Management Investment Advisory Inc. now owns 33,957 shares of the company’s stock worth $4,911,000 after acquiring an additional 2,171 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Morgan Stanley dropped their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Finally, Leerink Partners dropped their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Insider Activity

In related news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $157.24 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business has a fifty day simple moving average of $147.58 and a two-hundred day simple moving average of $156.00. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a market capitalization of $378.58 billion, a P/E ratio of 23.65, a P/E/G ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period last year, the business posted $2.29 earnings per share. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.15%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.